Kaufer D
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA.
Dement Geriatr Cogn Disord. 1998;9 Suppl 2:8-14. doi: 10.1159/000051193.
Preliminary studies suggest that non-cognitive behavioural and personality alterations in Alzheimer's disease may benefit from agents which inhibit central acetylcholinesterase (AChE). A double-blind, placebo-controlled, 26-week study of the AChE inhibitor metrifonate using the NeuroPsychiatric Inventory (NPI) to assess the effects of treatment on neuropsychiatric symptoms observed statistically significant mean change differences favouring treatment in the total NPI score and in symptoms of depression, apathy and hallucinations, as well as a nearly significant difference in aberrant motor behaviours. These data are consistent with previous studies and are believed to represent the first large prospective, controlled study demonstrating a beneficial effect of AChE inhibitor therapy on neuropsychiatric symptoms in Alzheimer's disease. The nature of non-cognitive symptom responses to AChE inhibitor therapy and their potential impact on caregivers is discussed.
初步研究表明，阿尔茨海默病患者的非认知行为和人格改变可能受益于抑制中枢乙酰胆碱酯酶（AChE）的药物。一项使用神经精神科问卷（NPI）对AChE抑制剂敌百虫进行的为期26周的双盲、安慰剂对照研究，以评估治疗对神经精神症状的影响，结果显示，在总NPI评分以及抑郁、冷漠和幻觉症状方面，治疗组的平均变化差异具有统计学意义，且异常运动行为方面也有接近显著的差异。这些数据与先前的研究一致，被认为是第一项大型前瞻性对照研究，证明了AChE抑制剂疗法对阿尔茨海默病神经精神症状具有有益作用。文中还讨论了AChE抑制剂疗法对非认知症状反应的性质及其对护理人员的潜在影响。
